TuHURA Biosciences, Inc. Common Stock
Market Cap
140M
Short interest (May 15)
12.5%
Net Short (Jun 03 ): 0.0%
Borrow Fee
19.12%
↑ 13.6%
Available Shares
70K
↓ 91.0%
Price Chart
Company Overview
TuHURA Biosciences Inc is a phase 3 clinical stage immuno-oncology company with three distinct technologies focused on the development of novel therapeutics designed to overcome primary and acquired resistance to cancer immunotherapies. The company's personalized cancer vaccine candidate, IFx-2.0, is designed to overcome primary resistance to checkpoint inhibitors. The company operates in one reportable segment, which includes all activities related to advancing therapies for cancer treatment.
Company Info
Market Data
Short Interest
Recent Changes
Quick Actions
Investment Risk
This is not financial advice. All investments carry risk. Do your own research before making investment decisions.